menu
    • menu
    [{"orgOrder":0,"company":"3M Company","sponsor":"Solventum","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"Solventum","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"Solventum","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"Solventum","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"Solventum","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"Solventum","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Swab","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"1","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"1","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase III","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3M Company \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"3M Company \/ Undisclosed"},{"orgOrder":0,"company":"3M Company","sponsor":"Solventum","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ethanol","moa":"Gamma-aminobutyric acid receptor subunit alpha-1; Glutamate receptor ionotropic, NMDA 3A; Glycine receptor subunit alpha-1; Glycine receptor subunit alpha-2; Voltage-dependent L-type calcium channel subunit beta-1; 5-hydroxytryptamine receptor 3A; Gamma-aminobutyric acid receptor subunit alpha-2; Neuronal acetylcholine receptor subunit alpha-10; Voltage-dependent L-type calcium channel subunit alpha-1C; Gamma-aminobutyric acid receptor subunit alpha-5; Gamma-aminobutyric acid receptor subunit alpha-4; Gamma-aminobutyric acid receptor subunit alpha-3; Glutamate receptor 1; Voltage-dependent calcium channel gamma-1 subunit; Neuronal acetylcholine receptor subunit alpha-2; Gamma-aminobutyric acid receptor subunit alpha-6; Glutamate receptor 2; Glutamate receptor 4; Glutamate receptor 3; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit beta-2; G protein-activated inward rectifier potassium channel 1; G protein-activated inward rectifier potassium cha","graph1":"Undisclosed","graph2":"Phase IV","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Foam","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Iodine Povacrylex","moa":"iodine-containing contrast media","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"1","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"Solventum","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tiotropium Bromide","moa":"Muscarinic acetylcholine receptor M3","graph1":"Undisclosed","graph2":"Phase I","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"6","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"Solventum","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tiotropium Bromide","moa":"Muscarinic acetylcholine receptor M3","graph1":"Undisclosed","graph2":"Phase I","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"6","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"Baiya Phytopharm","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"THAILAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"25 Baiya SARS-CoV-2 Vax 2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"6","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"IDRI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"3M-052","moa":"||Toll-like receptor 7 | Toll-like receptor 8","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"3M Company \/ IDRI","highestDevelopmentStatusID":"4","companyTruncated":"3M Company \/ IDRI"},{"orgOrder":0,"company":"3M Company","sponsor":"Solventum","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Sls Toothpaste","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Undisclosed","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Paste","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"1","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"NPWTi-d","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"1","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Swab","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Swab","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"7","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vanish XT","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase IV","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3M Company \/ 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"3M Company \/ 3M Company"},{"orgOrder":0,"company":"3M Company","sponsor":"Marin L. Schweizer, PhD","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"3M Company","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ointment","sponsorNew":"3M Company \/ Marin L. Schweizer, PhD","highestDevelopmentStatusID":"11","companyTruncated":"3M Company \/ Marin L. Schweizer, PhD"}]

    Find Clinical Drug Pipeline Developments & Deals by 3M Company

    Menu

    3M Company

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            3M Company

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            3M Company

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Povidone Iodine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Recipient : University of Iowa

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Povidone Iodine Nasal Application to Prevent Intraoperative Spread of SARS-CoV-2

                            Details : Povidone Iodine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 27, 2023

                            Lead Product(s) : Povidone Iodine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Recipient : University of Iowa

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            3M Company

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            3M Company

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 25 Baiya SARS-CoV-2 Vax 2

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : Baiya Phytopharm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            3M Adjuvant Boosts Immune Response to Plant-Based COVID-19 Vaccine in Thailand Clinical Trials

                            Details : Baiya’s SARS-CoV-2 Vax 2 is second-generation plant-produced vaccine modelled on prototype SARS-CoV-2 RBD antigen adjuvanted with 3M-052-AF-alum. Data from first cohort of 12 participants demonstrated no significant changes in vital signs during first ...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 29, 2022

                            Lead Product(s) : 25 Baiya SARS-CoV-2 Vax 2

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : Baiya Phytopharm

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            3M Company

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            3M Company

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 3M-052,Potassium Alum

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : IDRI

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            New Adjuvanted Vaccine Candidate Using IDRI Formulation Demonstrates Coronavirus Pan-Vaccine Potential

                            Details : Vaccine candidate, which combines a nanoparticle developed by a Duke-led research team with IDRI’s novel formulation of 3M’s “3M-052” compound Produced more “broadly neutralizing antibodies” against several strains of coronavirus, including b...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 03, 2021

                            Lead Product(s) : 3M-052,Potassium Alum

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : IDRI

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            3M Company

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            3M Company

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorhexidine Gluconate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Recipient : Solventum

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy Study of Patient Preoperative Preps In-vivo

                            Details : Chlorhexidine Gluconate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 16, 2021

                            Lead Product(s) : Chlorhexidine Gluconate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Recipient : Solventum

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            3M Company

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            3M Company

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sls Toothpaste

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Undisclosed

                            Recipient : Solventum

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            3M Oral Rinse Incidence and Patient Acceptance of Sloughing When Used With Sodium Lauryl Sulfate (SLS) Toothpa...

                            Details : Sls Toothpaste is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Oral Mucosal Disorder.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 23, 2020

                            Lead Product(s) : Sls Toothpaste

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Undisclosed

                            Recipient : Solventum

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            3M Company

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            3M Company

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Povidone Iodine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Recipient : Brigham and Women's Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I/II Trial of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy Subjects

                            Details : Povidone Iodine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 12, 2020

                            Lead Product(s) : Povidone Iodine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Brigham and Women's Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            3M Company

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            3M Company

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Povidone Iodine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Marin L. Schweizer, PhD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nasal Decolonization of Dialysis Patients Noses

                            Details : Povidone Iodine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Staphylococcal Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 24, 2019

                            Lead Product(s) : Povidone Iodine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Marin L. Schweizer, PhD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            3M Company

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            3M Company

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NPWTi-d

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Undisclosed

                            Recipient : KCI USA, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Negative Pressure Wound Therapy With Instillation of Saline Solution Versus Collagenase Ointment in Full-thick...

                            Details : NPWTi-d is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Wounds and Injuries.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 29, 2018

                            Lead Product(s) : NPWTi-d

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Undisclosed

                            Recipient : KCI USA, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            3M Company

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            3M Company

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vanish XT

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase IV

                            Recipient : University of Nebraska

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effectiveness of Resin-Modified Glass Ionomer Varnish in Preventing White Spot Lesions in Fixed Appliance Orth...

                            Details : Vanish XT is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dental Caries.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 18, 2018

                            Lead Product(s) : Vanish XT

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase IV

                            Recipient : University of Nebraska

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            3M Company

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            3M Company

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorhexidine Gluconate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Recipient : Solventum

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            In Vivo Preoperative Skin Preparation Efficacy Study Within a Defined Product Coverage Area

                            Details : Chlorhexidine Gluconate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 24, 2018

                            Lead Product(s) : Chlorhexidine Gluconate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Recipient : Solventum

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth